Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis.

Literature DB >> 4381646

Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis.

E W Jackson, C R Dorn, J K Saito, D G McKercher.

Abstract

Entities: Disease Species

Mesh：

Year: 1966 PMID： 4381646 DOI： 10.1038/211313a0

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

Authors: Diana L Thomas; Rosalinda Doty; Vesna Tosic; Jia Liu; David M Kranz; Grant McFadden; Amy L Macneill; Edward J Roy
Journal: Cancer Immunol Immunother Date: 2011-06-09 Impact factor: 6.968

2. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

Authors: Rosalinda A Doty; Jia Liu; Grant McFadden; Edward J Roy; Amy L MacNeill
Journal: Oncolytic Virother Date: 2013-01

3. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

Authors: Sonia Tusell Wennier; Jia Liu; Shoudong Li; Masmudur M Rahman; Mahmoud Mona; Grant McFadden
Journal: Mol Ther Date: 2012-01-10 Impact factor: 11.454

4. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

Authors: Marianne M Stanford; John W Barrett; Steven H Nazarian; Steven Werden; Grant McFadden
Journal: J Virol Date: 2006-11-15 Impact factor: 5.103

Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis.

1. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors.

2. Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.

3. Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.

4. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.

5. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo.

Review 6. The TORrid affairs of viruses: effects of mammalian DNA viruses on the PI3K-Akt-mTOR signalling pathway.

7. Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma.

8. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

9. Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.

Review 10. On the potential of oncolytic virotherapy for the treatment of canine cancers.